ライフサイエンスコーパス: type 5

1 re BARC type 3a bleeds with 12 fatal bleeds (type 5).

2 r HIV entry coreceptor CC chemokine receptor type 5.

3 ted by species C human adenoviruses, such as type 5.

4 ases (ZFNs) targeting C-C chemokine receptor type 5.

5 48 h postinfection as compared to adenovirus type 5.

6 otein 4.2, leads to hereditary spherocytosis type 5.

7 ions, improve the storage time of adenovirus type 5.

8 1.1, 3.5, and 2.2 mmol/l, respectively; wild type = 5.0 mmol/l).

9 ing DNA nanotechnology(4) with up to 22 tile types(5-11).

10 Aldo-keto reductase 1C3 (AKR1C3; type 5 17beta-hydroxysteroid dehydrogenase) is overexpre

11 Type 5 17beta-hydroxysteroid dehydrogenase, aldo-keto re

12 Its key steps are a purpurogallin-type (5 + 2)-cycloaddition, followed by fragmentation, v

13 d to type 1, 3b, and 4 OFF bipolar cells and type 5-2, XBC, 6, and 7 ON bipolar cells.

14 nthesis of functionalized alkyne oxazoles of type 5; (2) intramolecular Diels-Alder/retro-Diels-Alder

15 redict enhancer-gene connections across cell types(5,6).

16 mproved survival in patients with c-MET wild-type (5.7 v 3.6 months; P = .09) regardless of treatment

17 ORs and 95% CIs for overall beta-HPV and HPV types 5, 8, 15, 17, 20, 24, 36, and 38 association with

18 As for the type-specific analysis, types 5, 8, 15, 17, 20, 24, 36, and 38 showed a signific

19 in (TLCN, or intercellular adhesion molecule type 5), a protein associated with maturation of dendrit

20 ells express CXCR5 (C-X-C chemokine receptor type 5, a chemokine receptor required for homing to GCs)

21 spectrin give rise to spinocerebellar ataxia type 5, a neurodegenerative disease characterized by pro

22 neutralization and persistence of adenovirus type 5, a prevalent nonenveloped human virus, are depend

23 recent studies show that spastic paraplegia type 5, a progressive neuropathy, is caused by loss-of-f

24 e small Rep proteins, adeno-associated virus type 5 (AAV5) generates a Rep40-like protein by alternat

25 ns is appended to the adeno-associated virus type 5 (AAV5) helicase domain, the resulting protein for

26 of de novo-generated adeno-associated virus type 5 (AAV5) Rep52 and capsid proteins is part of the l

27 by local injection of adeno-associated virus type 5 (AAV5)-Cre into floxed-A2AR knockout mice.

28 heterotrimer binds to the N terminus (NT) of type 5 AC (AC5).

29 We now show that mAKAPbeta selectively binds type 5 AC in the heart and that mAKAPbeta-associated AC

30 of murine AnxA4 with human membrane-bound AC type 5 (AC5).

31 AC types 5 (ACV) and 6 (ACVI) are the 2 main isoforms in th

32 (6) plaque-forming-units (PFU) of adenovirus type 5 (Ad5) after corneal scarification.

33 isation was prestratified by sex, adenovirus type 5 (Ad5) antibody titre at baseline, and study site.

34 The E1b55K and E4orf6 proteins of adenovirus type 5 (Ad5) assemble into a complex together with cellu

35 were polyubiquitinated during AAV-adenovirus type 5 (Ad5) coinfection and during transient transfecti

36 ether mutations in regions of the adenovirus type 5 (Ad5) DNA polymerase that interact with the dNTP

37 osis induced by infection with an adenovirus type 5 (Ad5) E1B 19-kilodalton (E1B 19K) gene deletion m

38 The human adenovirus type 5 (Ad5) E1B 55-kDa protein modulates several cellul

39 The adenovirus type 5 (Ad5) early genes E1A and E1B can maintain lifelo

40 Human adenovirus type 5 (Ad5) encoding rat insulin promoter driven report

41 We generated recombinant adenovirus type 5 (Ad5) fiber knob, incorporating A20FMDV2 in the H

42 Results from Merck's phase II adenovirus type 5 (Ad5) gag/pol/nef test-of-concept trial showed th

43 Oncolytic viruses based on adenovirus type 5 (Ad5) have been developed as a new class of thera

44 proteins expressed from the E4 region of Ad type 5 (Ad5) inactivate the MRN complex by degradation a

45 Adenovirus type 5 (Ad5) inactivates the host cell DNA damage respon

46 OS are produced within minutes of adenovirus type 5 (Ad5) infection of macrophages and that oxidative

47 Adenovirus type 5 (Ad5) infection of macrophages results in rapid s

48 sociates with L4P and that during adenovirus type 5 (Ad5) infection, this association peaks at 12 h p

49 1 and Nbs1 are transient during wild-type Ad type 5 (Ad5) infection.

50 helicase (BLM) is degraded during adenovirus type 5 (Ad5) infection.

51 unctions would be targeted during adenovirus type 5 (Ad5) infection.

52 In wild-type Ad type 5 (Ad5) infections, E1b and E4 proteins target the

53 vel decreased significantly to 30% of the Ad type 5 (Ad5) mRNA level as measured by quantitative reve

54 Although several adenovirus type 5 (Ad5) proteins prevent deleterious consequences o

55 s received, sex, circumcision, or adenovirus type 5 (Ad5) serostatus.

56 Adenovirus type 5 (Ad5) specifically binds coagulation factor X (FX

57 rmined the structure of the human adenovirus type 5 (Ad5) to 3.6-A resolution and have reported the f

58 ck when an HIV-1 vaccine using an adenovirus type 5 (Ad5) vector failed to reduce, and might even hav

59 The biodistribution of adenovirus type 5 (Ad5) vector particles is heavily influenced by i

60 zed trial to determine whether an adenovirus type 5 (Ad5) vector vaccine, which elicits T cell immuni

61 inant replication-defective human adenovirus type 5 (Ad5) vector, Ad5-boIFN-lambda3, exhibited antivi

62 ral IgM inhibits gene transfer by adenovirus type 5 (Ad5) vectors.

63 ignificantly in cells infected by adenovirus type 5 (Ad5), but not in those infected by the E1B 55-kD

64 vesicular stomatitis virus (VSV), adenovirus type 5 (Ad5), rhesus monkey rhadinovirus (RRV), and DNA

65 The adenovirus type 5 (Ad5)-based vaccine developed by Merck failed to

66 usceptibility to HIV infection in adenovirus type 5 (Ad5)-seropositive, uncircumcised men.

67 vaccine with a booster dose of an adenovirus type 5 (Ad5)-vectored vaccine, or (3) a 3-dose regimen o

68 is the profound liver tropism of adenovirus type 5 (Ad5).

69 tissues are permissive for replication of Ad type 5 (Ad5).

70 g a newly constructed recombinant adenovirus type-5 (Ad5) that expresses enhanced jellyfish green flu

71 ministered through a replication incompetent type 5 adenovirus (Ad.mda-7) or with His-MDA-7/IL-24 pro

72 Type 5 adenovirus (Ad5) is a human pathogen that has bee

73 impedance spectroscopy for the detection of type 5 adenovirus.

74 sly showed that AKAP79/150 clusters PKA with type 5 adenylyl cyclase (AC5) to assemble a negative fee

75 For reasons that remain unclear, whether type 5 adenylyl cyclase (AC5), 1 of 2 major AC isoforms

76 mer (Galpha(s) x betagamma) and the effector type 5 adenylyl cyclase (AC5), localized by the N termin

77 Positional cloning reveals that fan encodes type 5 adenylyl cyclase (AC5).

78 zed monoclonal IgG1 against human adenovirus type 5 (AdV5) and a panel of Fc-engineered variants with

79 tion material selective for human adenovirus type 5 (AdV5) offered highly purified virus for the subs

80 ids influence the formation of RS similar to type 5, amylose-phenol complex.

81 n 4 (CD4) and coreceptors chemokine receptor type 5 and chemokine-related receptor type 4 (CCR5 and C

82 e improved the structure of human adenovirus type 5 and confirmed our previous models of cement prote

83 Our data suggest that spinocerebellar ataxia Type 5 and spectrin-associated autosomal recessive cereb

84 most prevalent, followed by type 3, type 2, type 5 and type 4 in that order.

85 currence of linked (L-type) and separated (S-type) 5S and 35S rDNA units, chromosome number, genome s

86 minor losses in affinity, Kd(mutant)/Kd(wild-type) and (ii) those where the apparent Kd was 50-

87 l cord when compared to the brain, while MOL types 5 and 6 (MOL5/6) increase their contribution to th

88 Active immunization with conjugated types 5 and 8 capsular polysaccharides, an iron scavengi

89 niae serotype 12F, and Staphylococcus aureus types 5 and 8 capsular polysaccharides.

90 cted with HPV genus beta-species 1 (includes types 5 and 8), than BCC samples (P=0.01); this differen

91 eport relative abundances of all lengths and types (5' and 3') of single-stranded overhangs, if prese

92 pression and replication by human adenovirus type 5, and dysregulates cellular glucose and lipid meta

93 generative syndromes, spinocerebellar ataxia Type 5, and spectrin-associated autosomal recessive cere

94 hmogenic cardiomyopathy/ARVC subtype is ARVC type 5 (ARVC5), caused by a p.S358L mutation in TMEM43 (

95 llowed by a replication-deficient adenovirus type 5 boost (10(10) particle units) encoding all DNA va

96 ficacy of a DNA prime-recombinant adenovirus type 5 boost (DNA/rAd5) vaccine regimen in persons at in

97 hree DNA primes and a recombinant adenovirus type 5 boost (weeks 0, 4, 8, and 24, respectively).

98 mulus, suggesting that Distal Arthrogryposis Type 5 can be caused by gain-of-function mutations in PI

99 Here, we report that the type 5 capsular polysaccharide (CP5) of Staphylococcus a

100 dular synthesis of the Staphylococcus aureus type 5 capsular polysaccharide repeating unit, a trisacc

101 -kDa protein-null mutant of human adenovirus type 5 carry a large number of posttranslational modific

102 were transduced with recombinant adenovirus type 5 carrying mouse Elovl4 and supplemented with 24:0,

103 and types 2 (CCL2), and C-C chemokine ligand types 5 (CCL5) in patients with alcoholic hepatitis.

104 enfuvirtide) and the C-C chemokine receptor type 5 (CCR5) blocker maraviroc (Selzentry).

105 r pleiotropic signaling of the C-C chemokine type 5 (CCR5) G protein-coupled receptor (GPCR) by predi

106 tor type 2 (Ccr2) and C-C chemokine receptor type 5 (Ccr5) in the livers of patients with ALD, and in

107 The C-C chemokine receptor Type 5 (CCR5) is a key receptor for human immunodeficien

108 P < .001), and plasma CC chemokine receptor type 5 (CCR5) ligand (macrophage-inflammatory protein 1b

109 that ORM1 can bind to C-C chemokine receptor type 5 (CCR5) on muscle cells and deletion of the recept

110 C-C chemokine receptor type 5 (CCR5) serves as a co-receptor for Human immunode

111 lenge levels of CD4(+)C-C chemokine receptor type 5 (CCR5)(+)HLA-DR(+) T cells in the rectal biopsies

112 ein-coupled receptor, C-C chemokine receptor type 5 (CCR5), in human disease since ancient times.

113 equencies of foreskin C-C chemokine receptor type 5(+) (CCR5(+)) T cells, T regulatory cells, and T-h

114 ent without fast-inactivating component; and type 5 cells, with a large outward rectifying current wi

115 l is a potent and selective inhibitor of the type 5 cGMP (cyclic guanosine 3',5'-monophosphate)-speci

116 ents with a subtype of Distal Arthrogryposis Type 5 characterized by generalized autosomal dominant c

117 with replication-deficient human adenovirus type 5 constructs and boosting with ex vivo plasmid-tran

118 s and replication-deficient human adenovirus type 5 constructs encoding large sections of canine SMCY

119 gained production of capsular polysaccharide type 5 (CP5) and staphyloxanthin.

120 , as exemplified by C-X-C chemokine receptor type 5 (CXCR5) upregulation.

121 is enriched with a C-X-C chemokine receptor type 5 (CXCR5)(+)CD4(+) TFH precursor phenotype.

122 pe of GS overlaps with distal arthrogryposis type 5 (DA5) and Marden-Walker syndrome (MWS).

123 DA type 5D (DA5D) is a rare, autosomal-recessive DA previou

124 (4) genome coverage by the different domain types, (5) degree of fit to a power-law distribution, (6

125 n with influenza B virus or human adenovirus type 5 did not induce significant levels of reporter exp

126 ain (conserved region 3 [CR3]) of adenovirus type 5 E1A (Ad5E1A) and requires the integrity of the en

127 In contrast, the nontumorigenic adenovirus type 5 E1A protein (E1A-5) and other E1A-12 mutants lack

128 s studies have indicated that the adenovirus type 5 E1B 55-kDa protein facilitates viral DNA synthesi

129 the mechanism by which the human adenovirus type 5 E1B 55-kDa protein protects against the antiviral

130 d target specificity displayed by adenovirus type 5 E4Orf6-E1B-55k as part of a cullin 5-containing E

131 Cells that are infected with adenovirus type 5 early in G1 of the cell cycle are predisposed to

132 f intraocular adenovirus-induced (adenovirus type 5 early region 1 [Ad5E1]) tumors in C57BL/6 mice.

133 ocular adenovirus-induced (Ad5E1; adenovirus type 5 early region 1) tumors are rejected in syngeneic

134 ng unit of S. aureus capsular polysaccharide type 5 equipped with capping methyl groups at the points

135 (60.7 +/- 6.3%), increased phosphodiesterase type 5 expression (167 +/- 13.7%) and decreased nitric o

136 dentified as the disease-causing gene in FHL type 5 (FHL-5).

137 Familial hemophagocytic lymphohistiocytosis type 5 (FHL5) is caused by defects in the Munc18b/STXBP2

138 o the low infection efficiency of adenovirus type 5 for B cells.

139 macromolecular complexes with two subunits: type 5 G protein beta (Gbeta5) and R7 binding protein (R

140 The type 5 G protein beta subunit (Gbeta5) can form complexe

141 (RGS9), which is constitutively bound to the type 5 G protein beta-subunit (beta5).

142 complex with the short splice isoform of the type 5 G-protein beta subunit (G beta 5) and the RGS9 an

143 tic development ensures expression of RGS9-2/type 5 G-protein beta subunit/R7BP complexes at postsyna

144 ls homozygous for the C-C chemokine receptor type 5 gene with 32-bp deletions (CCR5Delta32) are resis

145 n hemoglobin beta and C-C chemokine receptor type 5 genes have substantial off-target cleavage, espec

146 Decoration of human adenovirus type 5 (hAd5) with folate, a known cancer-targeting moie

147 man adenoviruses, including human adenovirus type 5 (HAdV-5), are not endogenous to macaques.

148 ptotic gene PUMA to FLS via human adenovirus type 5 (HAdV5) vectors has been tested as a therapeutic

149 familial hemophagocytic lymphohistiocytosis type 5 has identified the E132A mutation in the hydropho

150 ere given a replication-defective adenovirus type 5 HIV-1 gag vaccine in a randomized, blinded therap

151 nimals immunized with replicating adenovirus type 5 host range (Ad5hr) recombinant viruses expressing

152 t with replication-competent adenovirus (Ad) type 5 host range mutant (Ad5 h) expressing SIV gag and

153 ollowing priming with replicating adenovirus type 5 host range mutant (Ad5hr)-human immunodeficiency

154 osally with replication-competent adenovirus type 5 host range mutant (Ad5hr)-simian immunodeficiency

155 lly primed twice with replicating adenovirus type 5 host range mutant (Ad5hr)-SIV recombinants and sy

156 riming with replication-competent adenovirus type 5 host range mutant (Ad5hr)-SIV recombinants, follo

157 e microbicide-only group received adenovirus type 5 host range mutant empty vector and alum.

158 shown that sequential replicating adenovirus type 5 host range mutant human immunodeficiency virus/si

159 twice mucosally with replicating adenovirus type 5 host range mutant SIV env/rev, gag, and nef recom

160 The E6 proteins of the beta-HPV type 5 (HPV5), -8, -20, -22, -38, -76, -92, and -96, as

161 nicamycin treatment of cells expressing wild-type 5-HT(2A)R resulted in an altered electrophoretic mo

162 12A) mutant, when co-expressed with the wild-type 5-HT(3)A subunit, did not affect functional express

163 y coexpression of the membrane-tethered wild-type 5-HT2B receptor N terminus was not observed using a

164 Furthermore, by coexpressing a tethered wild-type 5-HT2B receptor N terminus with a 5-HT2B receptor b

165 II (CRABP-II) and fatty acid binding protein type 5 in adipocytes and skeletal muscle, leading to enh

166 we have examined the L4P of human adenovirus type 5 in detail and have defined its transcription star

167 ene, SPTBN2, associated with spinocerebellar type 5 in humans.

168 es to evaluate the role of phosphodiesterase type 5 inhibition as adjunctive medical therapy in patie

169 r been ascertained whether phosphodiesterase type 5 inhibition exerts an antiremodeling effect in non

170 e overload have shown that phosphodiesterase type 5 inhibition is beneficial; however, the use of pho

171 Chronic phosphodiesterase type 5 inhibition, at this stage, has an antiremodeling

172 yl-1-methylxanthine (IBMX; phosphodiesterase type 5 inhibitor and adenosine antagonist, 10 micromol/L

173 me that a single dose of a phosphodiesterase type 5 inhibitor is safe and well tolerated in patients

174 both nitric oxide and the phosphodiesterase type 5 inhibitor sildenafil in carefully selected patien

175 on of cGMP levels with the phosphodiesterase type 5 inhibitor sildenafil.

176 Sildenafil, a phosphodiesterase type 5 inhibitor, potentiates the actions of nitric oxid

177 properties of a selective phosphodiesterase type 5 inhibitor, sildenafil, in a model of diabetic car

178 c vessels with and without phosphodiesterase type 5 inhibitor.

179 effects were reversed by a phosphodiesterase type 5 inhibitor.

180 icial; however, the use of phosphodiesterase type 5 inhibitors in patients with aortic stenosis is co

181 potential clinical use of phosphodiesterase type 5 inhibitors in patients with coexisting LUTS and e

182 In men, medication such as phosphodiesterase type 5 inhibitors may be beneficial, and surgery remains

183 that sildenafil and other phosphodiesterase type 5 inhibitors may enhance the sensitivity of certain

184 lin receptor antagonist or phosphodiesterase type 5 inhibitors were continued in 15/27 patients (55%)

185 s metabolic modulators and phosphodiesterase type 5 inhibitors, are now being considered.

186 ylate cyclase stimulators, phosphodiesterase type 5 inhibitors, sodium nitrite and endothelin recepto

187 receptor antagonists, and phosphodiesterase type 5 inhibitors.

188 adrenoceptor agonists and phosphodiesterase type 5 inhibitors.

189 tor antagonists [47.3%] or phosphodiesterase type-5 inhibitors [25.3%]).

190 Treatment with phosphodiesterase type-5 inhibitors and oral or inhaled prostanoids was pe

191 ct of cataract surgery and phosphodiesterase type-5 inhibitors remains to be further studied on a lar

192 with cataract surgery and phosphodiesterase type-5 inhibitors.

193 Adenylyl cyclase type 5 knockout (AC5KO) mice have increased longevity an

194 ix type 2, two type 3, eight type 4, and two type 5 lesions were identified on T2-weighted MRI.

195 potential of a novel lipopeptide/adenovirus type 5 (Lipo/rAdv5) prime/boost mucosal vaccine for indu

196 FLAP inhibitors and the novel-type 5-LO inhibitors licofelone and sulindac sulfide exh

197 ainfluenza virus type 2, parainfluenza virus type 5, measles virus, mumps virus, Hendra virus, and Ni

198 Agonist stimulation of the type 5 metabotropic glutamate (mGlu5) receptor initiates

199 Type 5 metabotropic glutamate (mGlu5) receptors might be

200 excitatory synaptic transmission mediated by type 5 metabotropic glutamate (mGlu5) receptors was enha

201 oduces antinociception in rats by activating type 5 metabotropic glutamate receptors (mGlu(5)) in the

202 Here, we examine the significance of type 5 metabotropic glutamate receptors (mGluR5s) for be

203 The anomalous synaptic plasticity requires type 5 metabotropic glutamate receptors (mGluR5s), which

204 the authors investigated the effects of the Type-5 metabotropic glutamate receptors (mGluR5) positiv

205 ged derivative of the metabotropic glutamate type 5 (mGlu5) receptor negative allosteric modulator ra

206 e we show that D1 and metabotropic glutamate type 5 (mGlu5) receptors can form previously unknown het

207 lly blocking metabotropic glutamate receptor type 5 (mGluR5) activation in IL during extinction train

208 eductions in metabotropic glutamate receptor type 5 (mGluR5) binding in smokers and recent ex-smokers

209 decrease in metabotropic glutamate receptor type 5 (mGluR5) expression and reduced glutamate turnove

210 ctivation of metabotropic glutamate receptor type 5 (mGluR5) on interneuron spines leads to local GAB

211 ntagonist of metabotropic glutamate receptor type 5 (mGluR5) or its downstream signaling molecules (P

212 ctivation of metabotropic glutamate receptor type 5 (mGluR5) signaling and that this astrocyte-mediat

213 ligands for metabotropic glutamate receptor, type 5 (mGluR5), is essential to measure changes in brai

214 ntrations of metabotropic glutamate receptor type 5 (mGluR5).

215 ed with maturity-onset diabetes of the young type 5 (MODY5) and pancreas hypoplasia.

216 no pathogenic mutations in BRAF or KRAS), or type 5 (MSI-high, no CIMP, no pathogenic mutations in BR

217 egative for mutations in BRAF and KRAS); and type 5 (MSI-high, non-CIMP, negative for mutations in BR

218 Here, we identified type 5 NADPH oxidase (NOX5), a calcium-activated, ROS-fo

219 igand 5 that binds to C-C chemokine receptor type 5 on BCCs and BCCs secrete cytokine CSF1 that binds

220 K9) encodes the protein ATP13A2, a lysosomal type 5 P-type ATPase that is linked to autosomal recessi

221 PARK9 belongs to type 5 P-type ATPase with its putative function as a cat

222 in hexon; and noninfectious human adenovirus type 5 particles assembled in the absence of VII (Ad5-VI

223 tase, proprotein convertase subtilisin/kexin type 5 (PCSK5), causing inactive GDF11 precursor to accu

224 urin, proprotein convertase subtilisin/kexin type 5 (PCSK5), paired amino acid converting enzyme-4 (P

225 gnizing that inhibitors of phosphodiesterase type 5 (PDE5) are increasingly employed in patients with

226 ence suggests that reduced phosphodiesterase type 5 (PDE5) expression increases the invasiveness of m

227 In the normal heart, phosphodiesterase type 5 (PDE5) hydrolyzes cGMP coupled to nitric oxide- (

228 ne monophosphate-selective phosphodiesterase type 5 (PDE5) influences maladaptive remodeling in heart

229 Phosphodiesterase type 5 (PDE5) inhibition has been shown to exert profoun

230 ports an evolving role for phosphodiesterase type 5 (PDE5) inhibition in patients with pulmonary hype

231 oral sildenafil citrate, a phosphodiesterase type 5 (PDE5) inhibitor and potent vasodilator.

232 he effect of Sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, on nestin lineage neural stem c

233 rectile dysfunction drugs, phosphodiesterase type 5 (PDE5) inhibitors, is part of a pathway implicate

234 he cGMP-hydrolyzing enzyme phosphodiesterase type 5 (PDE5) might exert renoprotective effects in DN.

235 ophosphate (cGMP) specific phosphodiesterase type 5 (PDE5) plays an important role in various patholo

236 arkably similar to that of phosphodiesterase type 5 (PDE5), an enzyme that catalyzes the hydrolysis o

237 New York, NY), a selective phosphodiesterase type-5 (PDE5) inhibitor, is widely used to treat impoten

238 first randomized placebo-controlled trial of type-5 phosphodiesterase therapy in treatment-naive chil

239 aling molecules, including phosphodiesterase type 5, phosphorylated endothelial nitric oxide synthase

240 (IFN) alpha/beta against parainfluenza virus type 5 (PIV5), selectively inhibiting the translation of

241 in which the V protein of parainfluenzavirus type 5 (PIV5; formerly known as simian virus type 5 [SV5

242 genes, Legionella pneumophila, or adenovirus type 5, promoted a marked induction of IFN-beta mRNA exp

243 cGMP phosphodiesterase type 5 protein is upregulated in myocardial hypertrophy.

244 hat protein tyrosine phosphatase nonreceptor type 5 (PTPN5) (also known as STEP) is a critical determ

245 Protein tyrosine phosphatase non-receptor type 5 (PTPN5, STEP) is a brain specific phosphatase tha

246 prime vaccine, with a recombinant adenovirus type 5 (rAd5) boost, failed to protect from HIV-1 acquis

247 A priming followed by recombinant adenovirus type 5 (rAd5) boosting elicited CD8(+) T-cell-mediated a

248 egimens revealed that recombinant adenovirus type 5 (rAd5) prime followed by replication-defective ly

249 elope (Env) DNA/recombinant adenovirus virus type 5 (rAd5) vaccine studied in HIV-1 Vaccine Trials Ne

250 accine delivered with recombinant adenovirus type 5 (rAd5) vectors showed no efficacy in lowering vir

251 Boosting with recombinant Adenovirus type-5 (rAd5) vectors resulted in robust expansion of SI

252 cine trial (DNA prime/recombinant adenovirus type 5 [rAd5] boost) (VRC-10-332) that demonstrated subs

253 encoded by live recombinant human adenovirus type 5 (rAdHu5).

254 ompared with homozygous carriers of the wild-type 5 repeat allele (P = 0.03-0.0001).

255 ation activity relieves repression of oocyte-type 5 S rRNA genes and is correlated with a decrease in

256 repressor complex exclusively to the oocyte-type 5 S rRNA genes, leading to their terminal repressio

257 are present on oocyte-type, but not somatic-type, 5 S rRNA genes up through the neurula stage, as is

258 Spinocerebellar ataxia type 5 (SCA5) and spectrin associated autosomal recessiv

259 ion (L253P) linked to spinocerebellar ataxia type 5 (SCA5) causes a dramatic increase in actin bindin

260 Spinocerebellar ataxia type 5 (SCA5) is a neurodegenerative disease caused by m

261 Spinocerebellar ataxia type 5 (SCA5) is an autosomal dominant neurodegenerative

262 Spinocerebellar ataxia type 5 (SCA5) is an autosomal dominant neurodegenerative

263 A spinocerebellar ataxia type 5 (SCA5) L253P mutation in the actin-binding domain

264 Spinocerebellar ataxia type 5 (SCA5), a dominant neurodegenerative disease char

265 ink strongly to human spinocerebellar ataxia type 5 (SCA5), correlating with alterations in EAAT4.

266 linical phenotypes of spinocerebellar ataxia type-5 (SCA5) and spectrin-associated autosomal recessiv

267 logical diseases, hereditary spastic paresis type 5 (SPG5) and cerebrotendinous xanthomatosis (CTX),

268 Spastic paraplegia type 5 (SPG5) is a rare subtype of hereditary spastic pa

269 ions in the serine peptidase inhibitor Kazal type 5 (SPINK5) skin barrier gene have previously been a

270 ggrin (FLG), serine protease inhibitor Kazal-type 5 (SPINK5), and thymic stromal lymphopoietin (TSLP)

271 Thus, wild-type 5'ss D2 and ESEVif are required for production of s

272 cus sequence typing (MLST) revealed sequence type 5 (ST5) (n = 2), ST6 (n = 3), and ST185 (n = 1), wh

273 The sequence type 5 (ST5) Chilean-Cordobes clone, associated with CPT

274 MLST findings revealed that sequence type 5 (ST5) was the most predominant subtype (32/50).

275 MRSA (HA-MRSA) genotype (multilocus sequence type 5 [ST5] or SCCmec type II), the majority of mupA-po

276 type 5 (PIV5; formerly known as simian virus type 5 [SV5]) interacts with LGP2 and cooperatively inhi

277 ic deficiency of CC-chemokine receptor (CCR) type 5, the common receptor of chemokine (C-C motif) lig

278 esigned a replication-incompetent adenovirus type 5 to deliver a LANA-specific Cas9 system (Ad-CC9-LA

279 Transient receptor potential canonical type 5 (TRPC5) is a Ca(2+)-permeable cation channel that

280 The transient receptor potential vanilloid type 5 (TRPV5) Ca(2+) channel facilitates transcellular

281 h the transient receptor potential vanilloid type 5 (TRPV5) Ca(2+) channel.

282 type 2 and, the most divergent AAV serotype, type 5 TRs (TR2 or TR5).

283 Subjects with type 5 tumors had the lowest disease-specific mortality

284 targeting conserved genome regions of all EV types (5'UTR, 2 C, 3Dpol) were employed.

285 deliver a live recombinant human adenovirus type 5 vaccine vector (AdHu5) encoding HIV-1 gag.

286 polar cells most likely belonged to the CB3 (type 5) variety.

287 intramuscular prime/boost with an adenovirus type 5 vector induced a higher level of systemic CD8+ T

288 Human adenovirus type 5 vectors (rAd5) encoding ebolavirus glycoprotein (

289 We recently showed that clearance of Ad type 5 vectors by KCs does not involve the interaction o

290 inia virus Ankara) and Ad5 (human adenovirus type 5) vectors both expressing Ag85A in a single vaccin

291 Type 5 Vertucci's classification was the most frequently

292 interneurons were subjected to a 3 day binge-type 5% w/w ethanol consumption regimen from embryonic d

293 In each biopsy, EV-associated beta-HPV type 5 was identified (additionally, type 19 was found i

294 inhibitor of cGMP-specific phosphodiesterase type 5, was found to significantly reverse ABC-transport

295 Working with human adenovirus type 5, we showed previously that two proteins expressed

296 e nine known promoters from human adenovirus type 5 were analyzed for inherent DNA softness using the

297 ding beta-III spectrin (SPTBN2) underlie SCA type-5 whereas homozygous mutations cause spectrin assoc

298 ry artery bypass grafting (CABG)-related MI (type 5), which are of uncertain prognostic importance.

299 taphylococcus aureus capsular polysaccharide type 5, which is also a potential antigen for immunother

300 ctivation muscarinic acetylcholine receptors type 5, which mediate potentiation of dopamine transmiss